Stock Scorecard
Stock Summary for Pulmonx Corp (LUNG) - $2.05 as of 1/12/2026 5:28:42 PM EST
Total Score
11 out of 30
Safety Score
20 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for LUNG
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for LUNG
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for LUNG
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for LUNG
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for LUNG (20 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 1 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Financial Details for LUNG
Company Overview |
|
|---|---|
| Ticker | LUNG |
| Company Name | Pulmonx Corp |
| Country | USA |
| Description | Pulmonx Corporation (LUNG) is a pioneering medical technology firm headquartered in Redwood City, California, specializing in innovative treatments for chronic obstructive pulmonary disease (COPD). The company is renowned for its Zephyr® Endobronchial Valve, a minimally invasive solution that has demonstrated significant improvements in lung function and quality of life for patients with COPD while reducing procedural complications. With a strong focus on superior clinical outcomes and a comprehensive product portfolio, Pulmonx is strategically positioned to capture a significant share of the burgeoning respiratory disease market, addressing the urgent needs of millions of individuals affected by COPD. |
| Sector Name | HEALTHCARE |
| Industry Name | MEDICAL DEVICES |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 2.05 |
| Price 4 Years Ago | 8.43 |
| Last Day Price Updated | 1/12/2026 5:28:42 PM EST |
| Last Day Volume | 373,295 |
| Average Daily Volume | 787,787 |
| 52-Week High | 9.37 |
| 52-Week Low | 1.31 |
| Last Price to 52 Week Low | 56.49% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 56.69 |
| Sector PE | 123.98 |
| 5-Year Average PE | -8.93 |
| Free Cash Flow Ratio | 1.10 |
| Industry Free Cash Flow Ratio | 27.72 |
| Sector Free Cash Flow Ratio | 29.04 |
| Current Ratio Most Recent Quarter | 4.86 |
| Total Cash Per Share | 1.86 |
| Book Value Per Share Most Recent Quarter | 1.46 |
| Price to Book Ratio | 1.52 |
| Industry Price to Book Ratio | 4.82 |
| Sector Price to Book Ratio | 24.69 |
| Price to Sales Ratio Twelve Trailing Months | 0.95 |
| Industry Price to Sales Ratio Twelve Trailing Months | 4.22 |
| Sector Price to Sales Ratio Twelve Trailing Months | 19.33 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 41,247,000 |
| Market Capitalization | 84,556,350 |
| Institutional Ownership | 78.38% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 7.31% |
| Reported EPS 12 Trailing Months | -1.34 |
| Reported EPS Past Year | -1.08 |
| Reported EPS Prior Year | -1.40 |
| Net Income Twelve Trailing Months | -56,753,000 |
| Net Income Past Year | -56,394,000 |
| Net Income Prior Year | -60,843,000 |
| Quarterly Revenue Growth YOY | 5.50% |
| 5-Year Revenue Growth | 20.78% |
| Operating Margin Twelve Trailing Months | -66.90% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 76,549,000 |
| Total Cash Past Year | 70,905,000 |
| Total Cash Prior Year | 83,547,000 |
| Net Cash Position Most Recent Quarter | 39,524,000 |
| Net Cash Position Past Year | 36,903,000 |
| Long Term Debt Past Year | 34,002,000 |
| Long Term Debt Prior Year | 35,089,000 |
| Total Debt Most Recent Quarter | 37,025,000 |
| Equity to Debt Ratio Past Year | 0.72 |
| Equity to Debt Ratio Most Recent Quarter | 0.62 |
| Total Stockholder Equity Past Year | 85,809,000 |
| Total Stockholder Equity Prior Year | 118,315,000 |
| Total Stockholder Equity Most Recent Quarter | 60,033,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -32,618,999 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.79 |
| Free Cash Flow Past Year | -32,984,000 |
| Free Cash Flow Prior Year | -38,417,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.03 |
| MACD Signal | 0.09 |
| 20-Day Bollinger Lower Band | 1.23 |
| 20-Day Bollinger Middle Band | 1.88 |
| 20-Day Bollinger Upper Band | 2.53 |
| Beta | 0.11 |
| RSI | 43.64 |
| 50-Day SMA | 3.41 |
| 150-Day SMA | 7.50 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 1/10/2026 2:58:07 AM EST |